Literature DB >> 29312666

Optimal pembrolizumab dosing for non-small cell lung cancer: further studies still needed.

Hai-Yan Tu1, Qi Zhang1, Yi-Long Wu1.   

Abstract

Entities:  

Year:  2017        PMID: 29312666      PMCID: PMC5757035          DOI: 10.21037/jtd.2017.10.152

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN: 2072-1439            Impact factor:   2.895


× No keyword cloud information.
  17 in total

1.  Phase I Study of Pembrolizumab (MK-3475; Anti-PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors.

Authors:  Amita Patnaik; S Peter Kang; Drew Rasco; Kyriakos P Papadopoulos; Jeroen Elassaiss-Schaap; Muralidhar Beeram; Ronald Drengler; Cong Chen; Lon Smith; Guillermo Espino; Kevin Gergich; Liliana Delgado; Adil Daud; Jill A Lindia; Xiaoyun Nicole Li; Robert H Pierce; Jennifer H Yearley; Dianna Wu; Omar Laterza; Manfred Lehnert; Robert Iannone; Anthony W Tolcher
Journal:  Clin Cancer Res       Date:  2015-05-14       Impact factor: 12.531

2.  Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial.

Authors:  Roy S Herbst; Paul Baas; Dong-Wan Kim; Enriqueta Felip; José L Pérez-Gracia; Ji-Youn Han; Julian Molina; Joo-Hang Kim; Catherine Dubos Arvis; Myung-Ju Ahn; Margarita Majem; Mary J Fidler; Gilberto de Castro; Marcelo Garrido; Gregory M Lubiniecki; Yue Shentu; Ellie Im; Marisa Dolled-Filhart; Edward B Garon
Journal:  Lancet       Date:  2015-12-19       Impact factor: 79.321

3.  Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial.

Authors:  Naiyer A Rizvi; Julien Mazières; David Planchard; Thomas E Stinchcombe; Grace K Dy; Scott J Antonia; Leora Horn; Hervé Lena; Elisa Minenza; Bertrand Mennecier; Gregory A Otterson; Luis T Campos; David R Gandara; Benjamin P Levy; Suresh G Nair; Gérard Zalcman; Jürgen Wolf; Pierre-Jean Souquet; Editta Baldini; Federico Cappuzzo; Christos Chouaid; Afshin Dowlati; Rachel Sanborn; Ariel Lopez-Chavez; Christian Grohe; Rudolf M Huber; Christopher T Harbison; Christine Baudelet; Brian J Lestini; Suresh S Ramalingam
Journal:  Lancet Oncol       Date:  2015-02-20       Impact factor: 41.316

4.  Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.

Authors:  Martin Reck; Delvys Rodríguez-Abreu; Andrew G Robinson; Rina Hui; Tibor Csőszi; Andrea Fülöp; Maya Gottfried; Nir Peled; Ali Tafreshi; Sinead Cuffe; Mary O'Brien; Suman Rao; Katsuyuki Hotta; Melanie A Leiby; Gregory M Lubiniecki; Yue Shentu; Reshma Rangwala; Julie R Brahmer
Journal:  N Engl J Med       Date:  2016-10-08       Impact factor: 91.245

5.  Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial.

Authors:  Caroline Robert; Antoni Ribas; Jedd D Wolchok; F Stephen Hodi; Omid Hamid; Richard Kefford; Jeffrey S Weber; Anthony M Joshua; Wen-Jen Hwu; Tara C Gangadhar; Amita Patnaik; Roxana Dronca; Hassane Zarour; Richard W Joseph; Peter Boasberg; Bartosz Chmielowski; Christine Mateus; Michael A Postow; Kevin Gergich; Jeroen Elassaiss-Schaap; Xiaoyun Nicole Li; Robert Iannone; Scot W Ebbinghaus; S Peter Kang; Adil Daud
Journal:  Lancet       Date:  2014-07-15       Impact factor: 79.321

6.  Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma.

Authors:  Antoni Ribas; Omid Hamid; Adil Daud; F Stephen Hodi; Jedd D Wolchok; Richard Kefford; Anthony M Joshua; Amita Patnaik; Wen-Jen Hwu; Jeffrey S Weber; Tara C Gangadhar; Peter Hersey; Roxana Dronca; Richard W Joseph; Hassane Zarour; Bartosz Chmielowski; Donald P Lawrence; Alain Algazi; Naiyer A Rizvi; Brianna Hoffner; Christine Mateus; Kevin Gergich; Jill A Lindia; Maxine Giannotti; Xiaoyun Nicole Li; Scot Ebbinghaus; S Peter Kang; Caroline Robert
Journal:  JAMA       Date:  2016-04-19       Impact factor: 56.272

7.  Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.

Authors:  Hossein Borghaei; Luis Paz-Ares; Leora Horn; David R Spigel; Martin Steins; Neal E Ready; Laura Q Chow; Everett E Vokes; Enriqueta Felip; Esther Holgado; Fabrice Barlesi; Martin Kohlhäufl; Oscar Arrieta; Marco Angelo Burgio; Jérôme Fayette; Hervé Lena; Elena Poddubskaya; David E Gerber; Scott N Gettinger; Charles M Rudin; Naiyer Rizvi; Lucio Crinò; George R Blumenschein; Scott J Antonia; Cécile Dorange; Christopher T Harbison; Friedrich Graf Finckenstein; Julie R Brahmer
Journal:  N Engl J Med       Date:  2015-09-27       Impact factor: 91.245

8.  Systematic evaluation of pembrolizumab dosing in patients with advanced non-small-cell lung cancer.

Authors:  M Chatterjee; D C Turner; E Felip; H Lena; F Cappuzzo; L Horn; E B Garon; R Hui; H-T Arkenau; M A Gubens; M D Hellmann; D Dong; C Li; K Mayawala; T Freshwater; M Ahamadi; J Stone; G M Lubiniecki; J Zhang; E Im; D P De Alwis; A G Kondic; Ø Fløtten
Journal:  Ann Oncol       Date:  2016-04-26       Impact factor: 32.976

Review 9.  Ongoing clinical trials of PD-1 and PD-L1 inhibitors for lung cancer in China.

Authors:  Si-Yang Liu; Yi-Long Wu
Journal:  J Hematol Oncol       Date:  2017-07-05       Impact factor: 17.388

10.  Evaluation of dosing strategy for pembrolizumab for oncology indications.

Authors:  Tomoko Freshwater; Anna Kondic; Malidi Ahamadi; Claire H Li; Rik de Greef; Dinesh de Alwis; Julie A Stone
Journal:  J Immunother Cancer       Date:  2017-05-16       Impact factor: 13.751

View more
  5 in total

1.  Focused Ultrasound-Enhanced Delivery of Intranasally Administered Anti-Programmed Cell Death-Ligand 1 Antibody to an Intracranial Murine Glioma Model.

Authors:  Dezhuang Ye; Jinyun Yuan; Yimei Yue; Joshua B Rubin; Hong Chen
Journal:  Pharmaceutics       Date:  2021-02-01       Impact factor: 6.321

2.  Rational combination of an immune checkpoint inhibitor with CSF1R inhibitor-loaded nanoparticle enhances anticancer efficacy.

Authors:  Vaishali Malik; Hayat Anu Ranjani; Anujan Ramesh; Harriet Smith; Ashish A Kulkarni
Journal:  Drug Deliv Transl Res       Date:  2021-08-07       Impact factor: 4.617

3.  Association of Extended Dosing Intervals or Delays in Pembrolizumab-based Regimens With Survival Outcomes in Advanced Non-small-cell Lung Cancer.

Authors:  Kartik Sehgal; Anushi Bulumulle; Heather Brody; Ritu R Gill; Shravanti Macherla; Aleksandra Qilleri; Danielle C McDonald; Cynthia R Cherry; Meghan Shea; Mark S Huberman; Paul A VanderLaan; Glen J Weiss; Paul R Walker; Daniel B Costa; Deepa Rangachari
Journal:  Clin Lung Cancer       Date:  2020-06-05       Impact factor: 4.785

Review 4.  Cancer Immunotherapy Dosing: A Pharmacokinetic/Pharmacodynamic Perspective.

Authors:  Félicien Le Louedec; Fanny Leenhardt; Clémence Marin; Étienne Chatelut; Alexandre Evrard; Joseph Ciccolini
Journal:  Vaccines (Basel)       Date:  2020-10-31

5.  Association between body mass index, dosing strategy, and efficacy of immune checkpoint inhibitors.

Authors:  Murtaza Ahmed; Mitchell S von Itzstein; Thomas Sheffield; Shaheen Khan; Farjana Fattah; Jason Y Park; Vinita Popat; Jessica M Saltarski; Yvonne Gloria-McCutchen; David Hsiehchen; Jared Ostmeyer; Saad A Khan; Nazima Sultana; Yang Xie; Quan-Zhen Li; Edward K Wakeland; David E Gerber
Journal:  J Immunother Cancer       Date:  2021-06       Impact factor: 13.751

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.